megestrol acetate has been researched along with flutamide in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (47.62) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Curley, T; Dershaw, DD; Petrylak, D; Scher, HI; Seidman, AD | 1 |
| Cusan, L; Labrie, C; Labrie, F; Lapointe, S; Plante, M | 1 |
| Labrie, F; Lapointe, S; Plante, M | 1 |
| Sogani, PC; Whitmore, WF | 1 |
| Soloway, MS | 2 |
| Fair, WR; Sogani, PC | 1 |
| el Etreby, MF; Habenicht, UF; Louton, T; Nishino, Y; Schröder, HG | 1 |
| Bruchovsky, N; Fletcher, T; Foekens, JA; Goldenberg, SL; Lawson, D; Rennie, PS | 1 |
| Burton, S; Trachtenberg, J | 1 |
| Geller, J | 1 |
| Baird, A; Connors, KM; Geller, J; Hoffman, RM; Kohls, M; Sionit, LR | 1 |
| Burger, CW; Greggi, S; Kenemans, P; van der Vange, N; Vermorken, JB | 1 |
| McLeod, DG | 1 |
| Burch, PA; Loprinzi, CL | 1 |
3 review(s) available for megestrol acetate and flutamide
| Article | Year |
|---|---|
Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestrol Acetate; Prostatic Neoplasms | 1988 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Estrogens; Flutamide; Glucocorticoids; Humans; Ketoconazole; Male; Megestrol; Megestrol Acetate; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Spironolactone; Time Factors | 1987 |
Antiandrogenic drugs.
Topics: Androgen Receptor Antagonists; Anilides; Cyproterone Acetate; Diethylstilbestrol; Drug Administration Schedule; Flutamide; Humans; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds | 1993 |
2 trial(s) available for megestrol acetate and flutamide
| Article | Year |
|---|---|
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Diethylstilbestrol; Estramustine; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Megestrol; Megestrol Acetate; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Vinblastine | 1992 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Estrogens; Flutamide; Glucocorticoids; Humans; Ketoconazole; Male; Megestrol; Megestrol Acetate; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Spironolactone; Time Factors | 1987 |
17 other study(ies) available for megestrol acetate and flutamide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Topics: Adrenal Glands; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Organ Size; Ornithine Decarboxylase; Progesterone Congeners; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Spironolactone | 1987 |
Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice.
Topics: Androgens; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Female; Flutamide; Male; Mammary Neoplasms, Experimental; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Mice; Progesterone Congeners; Prostatic Neoplasms | 1988 |
Treatment of prostatic cancer. Newer forms of androgen deprivation.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestrol Acetate; Neoplasm Metastasis; Orchiectomy; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1986 |
Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats.
Topics: Adrenal Glands; Androgen Antagonists; Animals; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Male; Megestrol; Megestrol Acetate; Orchiectomy; Organ Size; Prostate; Rats; Rats, Inbred Strains; Seminal Vesicles | 1987 |
Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
Topics: Anilides; Animals; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Dihydrotestosterone; Flutamide; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Leuprolide; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Receptors, Androgen | 1988 |
Effectiveness of antiandrogens in the rat.
Topics: Androgen Antagonists; Animals; Flutamide; Imidazoles; Imidazolidines; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Seminal Vesicles; Testosterone | 1986 |
Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Topics: Adrenal Glands; Androgen Antagonists; Dihydrotestosterone; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Megestrol; Megestrol Acetate; Prostatic Neoplasms; Testis | 1985 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Megestrol; Megestrol Acetate; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1984 |
In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentrations in the human prostate.
Topics: Androgen Antagonists; Cell Division; Culture Techniques; Dihydrotestosterone; Fibroblast Growth Factor 2; Flutamide; Humans; Male; Megestrol; Megestrol Acetate; Orchiectomy; Prostate; Prostatic Hyperplasia; Radioimmunoassay | 1994 |
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Estrogen Antagonists; Female; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteolytic Agents; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Middle Aged; Ovarian Neoplasms; Progesterone Congeners; Remission Induction; Survival Rate; Tamoxifen; Triptorelin Pamoate | 1995 |
Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Humans; Male; Megestrol Acetate; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms | 1999 |